Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
22 public companies · 22 exchange-listed
22
Total Companies
22
Exchange Listed
17
Filed 10-K
7
States Represented
Total Sector Revenue
$10.98B
Aggregate of 15 companies with XBRL data
Avg Net Margin
-50.3%
Intensely competitive· Based on 15 filings
Sector Analysis · Sprytne.com
As of April 2026, the In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) reports a combined revenue of $10.98B across 15 SEC-tracked entities. With an average net margin of -50.3%, this industry is classified as loss-making on average. IDEXX LABORATORIES INC /DE leads the sector with $4.30B in reported revenue. The data is derived exclusively from official SEC EDGAR XBRL submissions and reflects the most recently filed 10-K annual reports.
Data aggregated from SEC EDGAR XBRL submissions · Updated March 2026
| Rank | Company | Revenue | Net Income | Net Margin | vs Industry Avg |
|---|---|---|---|---|---|
| #1 | IDEXX LABORATORIES INC /DEIDXX | $4.30B | $1.06B | 24.6% | +74.9pp |
| #2 | QuidelOrtho CorpQDEL | $3.27B | $-1,131,800,000 | -34.6% | +15.6pp |
| #3 | Lantheus Holdings, Inc.LNTH | $1.54B | $233.6M | 15.2% | +65.4pp |
| #4 | NEOGEN CORPNEOG | $894.7M | $-1,092,044,000 | -122.1% | -71.8pp |
| #5 | MYRIAD GENETICS INCMYGN | $824.5M | $-365,900,000 | -44.4% | +5.9pp |
| Industry Average | $731.9M | $-140,866,141 | -50.3% | baseline | |
ACHIEVE LIFE SCIENCES, INC.
CIK: 0000949858 · DE · 10-K: 2026-03-24
Alpha Teknova, Inc.
CIK: 0001850902 · DE · 10-K: 2026-03-02
Anbio Biotechnology
CIK: 0001982708 · E9
Asep Medical Holdings Inc.
CIK: 0001969766 · A1
Aspira Women's Health Inc.
CIK: 0000926617 · DE · 10-K: 2025-03-27
BIOMERICA INC
CIK: 0000073290 · DE · 10-K: 2025-08-29
BURZYNSKI RESEARCH INSTITUTE INC
CIK: 0000724445 · DE · 10-K: 2025-05-20
Cardio Diagnostics Holdings, Inc.
CIK: 0001870144 · DE · 10-K: 2026-03-13
Celldex Therapeutics, Inc.
CIK: 0000744218 · DE · 10-K: 2026-02-25
IDEXX LABORATORIES INC /DE
CIK: 0000874716 · DE · 10-K: 2026-02-20
IMMUCELL CORP /DE/
CIK: 0000811641 · DE · 10-K: 2025-03-28
Insight Molecular Diagnostics Inc.
CIK: 0001642380 · CA · 10-K: 2025-03-24
Intellia Therapeutics, Inc.
CIK: 0001652130 · DE · 10-K: 2026-02-26
Lantheus Holdings, Inc.
CIK: 0001521036 · DE · 10-K: 2026-02-26
MYRIAD GENETICS INC
CIK: 0000899923 · DE · 10-K: 2026-02-24
NEOGEN CORP
CIK: 0000711377 · MI · 10-K: 2025-07-30
NYMOX PHARMACEUTICAL CORP
CIK: 0001018735 ·
Q/C TECHNOLOGIES, INC.
CIK: 0001321834 · DE · 10-K: 2025-04-11
QuidelOrtho Corp
CIK: 0001906324 · · 10-K: 2026-02-19
TRINITY BIOTECH PLC
CIK: 0000888721 · L2
Virax Biolabs Group Ltd
CIK: 0001885827 · E9
VOLITIONRX LTD
CIK: 0000093314 · DE · 10-K: 2025-03-31